Press release
Sarepta Therapeutics Announces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic Year
– Recipients include 20 individuals living with Duchenne muscular dystrophy and five siblings of individuals living with Duchenne CAMBRIDGE, Mass.--(BUSINESS
About this update from Sarepta Therapeutics, Inc.
[{"type":"text","content":"\n– Recipients include 20 individuals living with Duchenne muscular dystrophy and five siblings of individuals living with Duchenne\n\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nSarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced 25 recipients of Route 79, The Duchenne Scholarship Program for the 2023-2024 academic year. Of the 25 recipients, academic scholarships will be awarded to 20 individuals living with Duchenne muscular dystrophy and to five siblings of individuals living with Duchenne. Each recipient will receive a scholarship of up to $5,000.\n\n\n“On behalf of Sarepta and the selection committee, we are proud to announce the recipients of Route 79, The Duchenne Scholarship Program, for the 2023-2024 academic year. We continue to be impressed by each applicant and this year, we selected a total of 25 exceptionally bright students with passion for growth and a strong vision for their future,” said Diane Berry, Sarepta’s Executive Vice President and Chief Global Policy & Advocacy Officer. “Each student’s essay demonstrated enthusiasm for their academic and life goals, a keen curiosity and admirable desire to learn, and the power of their own perseverance. We are honored to support this ambitious group of students and we wish them great success in their studies for the school year ahead.”\n\n\nThe Route 79 program was created in 2018 to recognize exceptional individuals living with Duchenne as they pursue their post-secondary education. In 2022, Sarepta expanded the program to include siblings of individuals with Duchenne in recognition of the impact that a diagnosis of Duchenne may have on the entire family. Recipients of the scholarship are chosen by an independent selection committee composed of Duchenne community members, who consider each applicant’s community involvement and personal essay. In addition to application review by the independent committee, submissions are de-identified for the voting panel with no indication of whether the candidate has received, or plans to receive, a Sarepta therapy.\n\n\n2023-2024 Route 79 Scholarship Recipients\n\n\n\nJohn \"Jack\" Becker, Embry-Riddle Aeronautical University, Daytona Beach\n\n\n\nChristopher Cameron, Ball State University\n\n\n\nJacob Colby, The Evergreen State College\n\n\n\nKyle Cox, Texas A&M Univers...